Changes in Strength of Recommendation and Perceived Barriers to Human Papillomavirus Vaccination: Longitudinal Analysis of Primary Care Physicians, 2008-2018
Overview
Authors
Affiliations
Objectives: To evaluate among pediatricians and family physicians human papillomavirus (HPV) vaccination recommendation practices for 11- to 12-year-old youth; report parental refusal/deferral of HPV vaccination; and report barriers to HPV vaccination changed over time.
Study Design: We surveyed nationally representative networks of pediatricians and family physicians in 2008, 2010, 2013-2014, and 2018. Male vaccination questions were not asked in 2008; barriers and parental vaccine refusal questions were not asked in 2010.
Results: Response rates were 80% in 2008 (680/848), 72% in 2010 (609/842), 70% in 2013-2014 (582/829), and 65% in 2018 (588/908). The proportion of physicians strongly recommending HPV vaccination for 11- to 12-year-old patients increased from 53% in 2008 to 79% in 2018 for female patients and from 48% in 2014 to 76% in 2018 for male patients (both P < .0001). The proportion of physicians indicating ≥50% of parents refused/deferred HPV vaccination remained steady for female patients (24% in 2008 vs 22% in 2018, P = .40) and decreased for male patients (42% in 2014 vs 28% in 2018, P < .001). Physician barriers to providing HPV vaccination were rare and decreased over time. Increasing numbers of physicians reported perceived parental barriers of vaccine safety concerns (5% "major barrier" in 2008 vs 35% in 2018, P < .0001) and moral/religious concerns (5% in 2008 vs 25% in 2018, P < .0001).
Conclusions: Between 2008 and 2018, more primary care physicians reported recommending HPV vaccination for adolescents, fewer reported barriers, and more physicians reported parents who had vaccine safety or moral/religious concerns.
Effect of School HPV Vaccination Requirements on Pediatricians' Recommendations.
Hedrick McKenzie A, Savas L, Shegog R, Mantey D, Frost E, Yeh P Vaccines (Basel). 2025; 12(12.
PMID: 39772037 PMC: 11680108. DOI: 10.3390/vaccines12121374.
Tsegaye A, Lin J, Cole A, Szpiro A, Rao D, Walson J J Community Health. 2024; 49(5):857-868.
PMID: 38485802 DOI: 10.1007/s10900-024-01333-w.
Coleman D, Markham C, Guilamo-Ramos V, Santa Maria D BMC Public Health. 2024; 24(1):265.
PMID: 38263012 PMC: 10804600. DOI: 10.1186/s12889-024-17653-4.
Kong W, Oh N, Kennedy K, Carlson R, Liu A, Ozawa S J Adolesc Health. 2024; 74(5):868-877.
PMID: 38231146 PMC: 11031337. DOI: 10.1016/j.jadohealth.2023.11.016.
Reimbursement for HPV Vaccine Cost in the Private Sector: A Comparison Across Specialties.
Zhu Y, Lin Y, Li R, He C, Lairson D, Deshmukh A Ann Fam Med. 2023; 21(4):344-346.
PMID: 37487718 PMC: 10365861. DOI: 10.1370/afm.2990.